Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,783 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Crisis in Uganda.
Bennett JA, Moore JR, Brown IR, Schram R, Davidson NM, Stanfield JP, Egdell HG, Tibbutt DA, Fellows GJ, Weller SD. Bennett JA, et al. Among authors: moore jr. Lancet. 1980 Apr 12;1(8172):826. doi: 10.1016/s0140-6736(80)91322-7. Lancet. 1980. PMID: 6102708 No abstract available.
Purpura after warfarin.
Moore JR. Moore JR. Lancet. 1967 Sep 2;2(7514):516. doi: 10.1016/s0140-6736(67)91695-9. Lancet. 1967. PMID: 4166424 No abstract available.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Don't Sleep on Sleep: A Case Report from a Division I Heptathlete.
Allen SMF, Bartaczewicz BL, Molenhouse AE, Redinger AL, Spokely NJ, Anderson OK, Montgomery SA, White GE, Moore JR, Joyce JM, Baker BS. Allen SMF, et al. Among authors: moore jr. J Athl Train. 2024 Dec 28. doi: 10.4085/1062-6050-0537.24. Online ahead of print. J Athl Train. 2024. PMID: 39731214 Free article.
1,783 results